Recital 4, Regulation (EU) 2023/949

In forcesince 12 May 2023

On 16 June 2020, the applicant also made a request to the Commission for the protection of proprietary data for an in vitro study on the digestibility of iron milk proteinate under simulated gastric conditions [Société des Produits Nestlé S.A. (2020, unpublished).]; the certificates of the compositional analyses of the production batches of iron proteinate [Société des Produits Nestlé S.A. (2020, unpublished).]; an in vitro study on the impact of ascorbic acid on the iron bioavailability of iron milk proteinate [Sabatier M, Rytz A, Husny J, Dubascoux S, Nicolas M, Dave A, Singh H, Bodis M and Glahn RP, 2020 Impact of ascorbic acid on the in vitro iron bioavailability of a casein-based ironfortificant. Nutrients, 12, 2776.https://doi.org/10.3390/nu12092776]; a randomised human study with a cross over design on the bioavailability of iron from whole milk containing iron milk proteinate as compared to ferrous sulfate [Henare SJ, Singh NN, Ellis AM, Moughan PJ, Thompson AK and Walczyk T, 2019. Iron bioavailability of a casein-based iron fortificant compared with that of ferrous sulfate in whole milk: a randomized trial with a crossover design in adult women. The American Journal of Clinical Nutrition, 110, 1362–1369.]; an acute oral toxicity study in rodents [Société des Produits Nestlé S.A. (2019, unpublished).]; a report on the intake assessment of iron milk proteinate resulting from the proposed uses [Société des Produits Nestlé S.A. (2020, unpublished).]; a literature search study strategy and results conducted by the applicant [Société des Produits Nestlé S.A. (2020, unpublished).]; and an iron bioaccessibility study from iron casein complexes produced with milk [Société des Produits Nestlé S.A. (2021, unpublished).], submitted in support of the application.